Oncology Times Highlights ERX-41

Carlton Hoyt, October 10, 2022

Dallas, Texas. October 10, 2022:

etiraRx’s lead drug candidate, ERX-41 has been highlighted in the most recent edition of Oncology Times. In an article entitled “Molecule Targets Vulnerability in Triple-Negative Breast Cancer,” Dibash Kumar Das, PhD, summarizes the findings published in the recent Nature Cancer article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” and interviews co-author Jung-Mo Ahn, PhD, Associate Professor of Chemistry at The University of Texas at Dallas.

You can read the full article at https://journals.lww.com/oncology-times/fulltext/2022/10050/molecule_targets_vulnerability_in_triple_negative.13.aspx

Related Post

• One year later, highest almetric score for any paper published in Nature Cancer!
• Positive preclinical data presented at AACR 2023
• Etira founder Dr. Ratna Vadlamudi honored with the prestigious 2023 Distinguished Research Scholar Award
• Preclinical data on TNBC presented at SABCS 2022
• Etira founder Dr. Jung-Mo Ahn highlighted in local press